Rui Yang, CEOAsymBio is built to be that end-to-end partner, where a single program follows a specific molecule, covering early developability assessment, technology transfer, manufacturing and regulatory affairs and filing support. Founded in 2019 as a subsidiary of Asymchem Group, AsymBio covers a broad range of biologics modalities, from conventional antibody and protein formats to bispecific and trispecific antibodies, advanced ADC formats and other novel conjugates.
“Our integrated model enables technical decisions, project risks, key milestones and manufacturing requirements to be considered together across the development pathway, helping clients accelerate their programs toward clinical and commercial stages,” says Rui Yang, CEO.
Connecting Expertise Across the Asymchem Ecosystem
Bioconjugate programs particularly benefit from this model. Developing an ADC requires coordinated expertise across small-molecule chemistry, protein science and conjugation technology. AsymBio’s Shanghai operations provide biologics and bioconjugate capabilities, while Asymchem Group’s Tianjin operations specialize in small-molecule chemistry and highly potent APIs for drug payload development. It unifies the Chemistry, Manufacturing and Controls (CMC) requirements of an ADC program under a single development and manufacturing model.
The company also extends support upstream, through AccPCC (Accelerated PCC), a newly launched R&D acceleration platform that combines AI-enabled tools with CMC, non-clinical and clinical capabilities, to expedite science-to-clinic translation. AsymBio provides lead optimization, developability assessment and early-stage CMC strategy. Yugen Medtech, the equity subsidiary of Asymchem Group, handles the non-clinical work, covering DMPK, in vitro and in vivo pharmacology and toxicology studies, while Asymchem Clinical (Clin-nov), also a subsidiary of Asymchem Group, handles the clinical side through translational medicine and early clinical strategy support.
These capabilities are coordinated through a unified framework, allowing clients to assess a candidate’s developability and feasibility before it is even selected, and ensuring it then moves from non-clinical studies to human trials under a single CDMO partner.
Its technology is reinforced by experience. AsymBio folds project learning into its platform knowledge base, letting new programs build on established scientific understanding. Beyond technical capabilities, AsymBio gives clients flexibility, visibility and control throughout development. Whether supporting an end-to-end program or a targeted engagement, the company keeps clients informed of timelines, risks and key decisions. All project IP, data and project-generated results are fully client-owned, protected through confidentiality, data-security and access-control practices. Its quality-management system is designed to meet the National Medical Products Administration, Food and Drug Administration and European Medicines Agency requirements.
Connecting Technology, Data and Experience
AsymBio’s technology platforms, spanning AmigoCHOTM Cell Line Development Platform, Upstream and Downstream Process Development Platforms, Payload-Linker CMC Platform, Conjugation Toolbox and IMPACT Drug Product Development Platform, function as a connected system. Upstream data guides downstream purification and formulation, while conjugation results inform payload-linker strategy and scale-up, sharpening CMC decisions on manufacturability and quality.
-
Our integrated model enables technical decisions, project risks, key milestones and manufacturing requirements to be considered together across the development pathway, helping clients accelerate their programs toward clinical and commercial stages.
Its technology is reinforced by experience. AsymBio folds project learning into its platform knowledge base, letting new programs build on established scientific understanding. Beyond technical capabilities, AsymBio gives clients flexibility, visibility and control throughout development. Whether supporting an end-to-end program or a targeted engagement, the company keeps clients informed of timelines, risks and key decisions. All project IP, data and project-generated results are fully client-owned, protected through confidentiality, data-security and access-control practices. Its quality-management system is designed to meet the National Medical Products Administration, Food and Drug Administration and European Medicines Agency requirements.
The track record shows. AsymBio’s accumulated experience includes more than 1000 early-development and preclinical projects, over 100 IND-stage programs, eight BLA-stage projects and two commercial payload-linker projects. It can also support a development path of 13–15 months to IND and 24–30 months to BLA submission.
Expanding the Development Pathway
AsymBio’s dual manufacturing sites in Shanghai, at Jinshan and Fengxian, support clients across different program stages and scales for both antibodies and bioconjugates. Jinshan primarily handles toxicology batches, clinical manufacturing and commercial production, while Fengxian focuses on late-stage clinical programs and large-scale commercial manufacturing.
This aligns manufacturing resources with a program’s stage, scale and supply needs, giving clients greater flexibility while reducing capacity and supply risks. A new R&D facility is also under construction in the same area, which will improve coordination across AsymBio’s broader manufacturing network.
The diverse yet connected capabilities show that AsymBio remains engaged with a program at every stage, fortifying its position as a strategic development partner—one that stays with a molecule and the client throughout the journey.
Selecting an Integrated Biologics CDMO for Development Continuity
Biologics programs can lose time at the handoffs between early development and manufacturing. A cell line may be technically sound yet create downstream purification burdens, while formulation choices made too late can complicate scale-up, stability work, technology transfer and filing preparation. For executives choosing an integrated biologics CDMO, the central question is not how many services sit on one menu. It is whether decisions made at one stage remain visible to the teams responsible for the next stage.
That distinction becomes visible in project governance. Sponsors need enough transparency to understand schedule movement before a missed milestone becomes a broader program delay. Useful oversight ties risk records to decision history and milestone changes while keeping manufacturing assumptions visible, so technical consequences remain traceable. Integration has little practical value if the sponsor still has to reconstruct why a process choice was made or which downstream activity it affects.
Development continuity deserves close scrutiny because biologics rarely move in a straight line. Changes in upstream conditions can affect downstream recovery and product quality. Analytical findings can force revisions to process parameters or formulation plans. A CDMO that treats each function as a separate assignment leaves the sponsor to reconcile technical assumptions and timing between groups. A more useful model keeps development data connected across process design, analytical characterization, formulation work and technology transfer. That continuity can shorten decision cycles without reducing the sponsor’s control over the program.
[QUOTE1_Replace]
Complex bioconjugates raise the bar further. Antibody-drug conjugates and related formats bring biologic development into direct contact with payload-linker chemistry, conjugation work, analytical control and drug product planning, creating interfaces that can become schedule risks when different suppliers own different portions of the molecule. Buyers should examine whether the provider can coordinate those interfaces under one CMC plan while preserving clear ownership of project data and intellectual property. The strongest evidence is not service breadth by itself. It is the ability to carry technical information from molecule assessment into manufacturing decisions without forcing the sponsor to rebuild context at every handoff.
Capacity also has to be judged as a planning issue rather than a headline number. Early programs need access to an appropriate scale, while late-stage work requires room for larger batches and dependable technology transfer. A manufacturing network becomes more useful when sites have complementary roles and when development teams remain closely connected to production teams. That arrangement can reduce exposure to single-site scheduling pressure and give sponsors more options as supply requirements change. Quality systems and regulatory support matter for the same reason. Development records, analytical packages, manufacturing history and filing support should remain coherent as the molecule advances.
These buying pressures make AsymBio a well-matched choice for sponsors that want one coordinated path across biologics development and manufacturing. Its scope connects cell line development with upstream and downstream process work, drug substance and drug product manufacturing, analytical support and regulatory filing assistance. For bioconjugates, AsymBio can link Shanghai-based biologics and conjugation work with Asymchem Group’s payload-linker capabilities in Tianjin, reducing the number of external interfaces a sponsor must manage. Its Jinshan and Fengxian sites provide complementary manufacturing options across clinical and commercial stages. This combination helps keep technical decisions and manufacturing planning connected as a molecule advances while the sponsor retains ownership of project assets.
...Read more
